H2AX and neoplasm: The potential of quantifying γ-H2AX in PBLs for predicting both individual subclinical haematotoxicity and tumour response to somatostatin receptor-targeted radioligand therapy was demonstrated by Derlin T et al. and Denoyer et al. where subclinical hematotoxicity was associated with γ-H2AX and 53BP1 foci formation (101, 102).